Five things for pharma marketers to know: Friday, April 15, 2016

1. Bristol-Myers Squibb is seeking a new indication for Opdivo, its immunotherapy treatment. The FDA has accepted the drugmaker's application to expand use to patients with difficult-to-treat variations of Hodgkin lymphoma. (WSJ)

2. Democratic presidential candidate Hillary Clinton received at least $2.85 million in speaking fees from the healthcare industry between 2013 and 2015. (Politico)

3. Quest Diagnostics created two tests that can predict whether a pair of new hepatitis-C treatments — Merck's Zepatier and Bristol-Myers Squibb's Daklinza —will treat the disease or if the virus will resist the therapies. (AP)

4. A new study found that the benefits and side effects of new cancer drugs are rarely included on the label. Only three of the 40 new drugs approved by the FDA over a five-year period listed reports of patient experiences. (Reuters)

5. A new report says that payers may need to provide incentives to physicians to prescribe biosimilars. The report was released by the Pharmaceutical Care Management Association, which represents PBMs.